American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Louisville

About this trial

The purpose of this study is to create a registry to provide insight into treatment selection and treatment outcome of pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer requiring surgical interventions.

The investigators seek a better understanding of the uses of ablation in the treatment of unresectable soft tissue pancreatic tumors and the limitations, concerns and complications that earlier users have.

Eligibility criteria

Qualifiers

Adult patients (greater than 18 years of age) diagnosed with pancreatic cancer that are eligible for soft tissue ablation per the treating physician.

Disqualifiers

Have a cardiac pacemaker or ICD implant

Non-removable implants with metal parts near target lesion

Myocardial infarction within 3 months prior to enrollment

Not suitable for general endotracheal anesthesia

Trial design

Treatments tested in this trial

  • Registry

Treatment groups

No treatment groups listed

Sponsors and collaborators

University of Louisville

Lead sponsor

The Americas Hepato-Pancreato-Biliary Association

Collaborator